

(19)  Canadian Intellectual Property Office An Agency of Industry Canada	Office de la Propriété Intellectuelle du Canada Un organisme d'Industrie Canada	(11) CA 2 442 479 (40) 23.11.2000 (43) 23.11.2000	(13) A1
---	---	--	----------------

(12)

(21) 2 442 479

(22) 13.05.1999

(51) Int. Cl.⁷: **A61K 31/5575, A61P 15/00, A61P 17/02, A61K 9/06, A61K 47/10, A61K 47/18, A61K 47/36**

(60) 21.10.2003 (62) 2373821 (71) NEXMED HOLDINGS, INC., 350 Corporate Blvd., ROBBINSVILLE, XX (US).	(72) BUYUKTIMKIN, NADIR (US). BUYUKTIMKIN, SERVET (US). YEAGER, JAMES L. (US). (74) MBM & CO.
--	--

(54) COMPOSITIONS TOPIQUES D'APPORT DE PROSTAGLANDINE E1

(54) TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E1 DELIVERY

(57)

A topical composition of a semi-solid consistency suitable is provided for transdermal application of prostaglandin E1. The composition comprises prostaglandin E1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)- alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

BEST AVAILABLE COPY

AP



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2442479 A1 2000/11/23

(21) **2 442 479**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(22) Date de dépôt/Filing Date: 1999/05/13

(41) Mise à la disp. pub./Open to Public Insp.: 2000/11/23

(62) Demande originale/Original Application: 2 373 821

(51) Cl.Int.⁷/Int.Cl.⁷ A61K 31/5575, A61K 47/36, A61K 47/18,
A61K 47/10, A61K 9/06, A61P 17/02, A61P 15/00

(71) Demandeur/Applicant:
NEXMED HOLDINGS, INC., US

(72) Inventeurs/Inventors:
YEAGER, JAMES L., US;
BUYUKTIMKIN, NADIR, US;
BUYUKTIMKIN, SERVET, US

(74) Agent: MBM & CO.

(54) Titre : COMPOSITIONS TOPIQUES D'APPORT DE PROSTAGLANDINE E₁

(54) Title: TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E₁ DELIVERY

(57) Abrégé/Abstract:

A topical composition of a semi-solid consistency suitable is provided for transdermal application of prostaglandin E₁. The composition comprises prostaglandin E₁, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>

OPIC • CIPQ 191

OPIC



CIPQ

-1-

Abstract

A topical composition of a semi-solid consistency suitable is provided for transdermal application of prostaglandin E1. The composition comprises prostaglandin E1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.


-1a-

TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E₁ DELIVERYTechnical Field of the Invention

5 This invention relates to pharmaceutical compositions for transdermal or transmucosal administration of prostaglandin drugs to a patient.

Background of the Invention

10 Prostaglandin E₁ is a derivative of prostanoic acid, a 20-carbon atom lipid acid, represented by the formula:



and is commercially available, e.g., from Chinoin Pharmaceutical and Chemical Works Ltd. (Budapest, Hungary) under the designation "Alprostadi USP" and from The Upjohn Company (Kalamazoo, Michigan) under the designation "Prostin VR."

20 Prostaglandin E₁ is a vasodilator useful to maintain open blood vessels and therefore, to treat peripheral vascular disease among other ailments. While the potential benefits from transdermal delivery of prostaglandin E₁ have long been recognized, prior efforts at developing a topical composition for prostaglandin delivery have not been fully successful.

25 In particular, there is presently no commercial source for a topical semi-solid formulation that is useful without a supporting device such as a patch, adhesive strip, and the like. For example, U.S. Patent No. 5,380,760 to Wendel et al. is directed to a topical prostaglandin formulation that includes a pressure-sensitive, adhesive sheet of

- 2 -

polyisobutylene.

Working alone most drugs, prostaglandin formulations included, do not sufficiently permeate the skin to provide drug concentration levels comparable to those obtained from other drug delivery routes. To overcome this problem, topical drug formulations typically include a skin penetration enhancer. Skin penetration enhancers also may be referred to as absorption enhancers, accelerants, adjuvants, solubilizers, sorption promoters, etc. Whatever the name, such agents serve to improve drug absorption across the skin. Ideal penetration enhancers not only increase drug flux across the skin, but do so without irritating, sensitizing, or damaging skin. Furthermore, ideal penetration enhancers should not affect available dosage forms (e.g. cream or gel), or cosmetic quality of the topical composition.

A wide variety of compounds have been evaluated as to their effectiveness in enhancing the rate of penetration of drugs through the skin. See, for example, *Percutaneous Penetration Enhancers*, Maibach H. I. and Smith H. E. (eds.), CRC Press, Inc., Boca Raton, F.L. (1995), which surveys the use and testing of various skin penetration enhancers, and Büyüktimkin et al., *Chemical Means of Transdermal Drug Permeation Enhancement in Transdermal and Topical Drug Delivery Systems*, Gosh T.K., Pfister W.R., Yum S.I. (Eds.), Interpharm Press Inc., Buffalo Grove, I.L. (1997).

A fully successful formulation for prostaglandin E₁ has not yet been identified. Unfortunately, prostaglandin E₁ is readily transformed by rearrangement and other reactions. This relative instability tends to complicate efforts at formulating composition for transdermal delivery.

The present invention addresses these problems by providing a semi-solid, separation resistant composition for relatively rapid, sustained delivery of prostaglandin E₁.

Summary of the Invention

A pharmaceutical composition suitable for topical application comprises prostaglandin E₁, a penetration enhancer,

- 3 -

a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The
5 lipophilic compound may be an aliphatic C₁ to C₈ alcohol, an aliphatic C₈ to C₃₀ ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4. If desired, stabilizers and emulsifiers may be
10 included.

Compositions of the present invention can take the form of a semi-solid suitable for topical application. In use as a topical agent, these compositions exhibit relatively high prostaglandin penetration and bioavailability without requiring
15 a wasteful overloading prostaglandin concentration. The compositions further exhibit reduced skin irritation, sensitivity and damage.

The prostaglandin compositions of the present invention are useful for the treatment of diseases such as
20 Raynaud's phenomenon, Raynaud's disease, Buerger's disease, livedo reticularis, acrocyanosis atherosclerosis, frostbite, vitiligo, alopecia areata, impending gangrene, and other ischemic disorders. Moreover, the ability of the topical prostaglandin compositions of the present invention to increase
25 peripheral circulation renders them useful to enhance the rate of healing of wounds, ulcers, infections and proliferative and inflammatory skin lesions including atopic dermatitis, acne and psoriasis; to treat impotency; or to enhance the rate of absorption of pharmaceutically active agents. In addition, the
30 topical prostaglandin compositions of the present invention may be employed to improve skin color and to promote blush.

The compositions of the present invention can thus be used for the manufacture of pharmaceutical compositions and medicaments that are suitable for the prolonged treatment of
35 peripheral vascular disease, including the conditions listed above, male erectile dysfunction, female sexual dysfunction and

- 4 -

other disorders treated by prostaglandin E₁, while avoiding the low bioavailability and rapid chemical decomposition associated with other delivery methods.

Other and further aims, purposes, features, advantages, embodiments and the like will be apparent to those skilled in the art from the present specification and the appended claims.

Brief Description of the Drawings

10 In the drawings,

FIGURE 1 is a graph of the cumulative prostaglandin E₁ penetration through shed snake skin of seven prostaglandin E₁ compositions prepared according to the present invention;

15 FIGURE 2 is a comparison graph of the cumulative prostaglandin E₁ penetration through shed snake skin of two prostaglandin E₁ compositions prepared according to the present invention and two comparative compositions.

Detailed Description of the Invention

20 The pharmaceutical composition of the present invention comprises prostaglandin E₁, an alkyl (N,N-disubstituted amino) ester, a polysaccharide gum, a lipophilic compound, and an acid buffer system.

25 Prostaglandin E₁ is well known to those skilled in the art. Reference may be had to various literature references for its pharmacological activities, side effects, and normal dosage ranges. See for example, *Physician's Desk Reference*, 51st Ed. (1997), *The Merck Index*, 12th Ed., Merck & Co., N.J. (1996), and *Martindale The Extra Pharmacopoeia*, 28th Ed., 30 London, The Pharmaceutical Press (1982). Prostaglandin E₁ as well as other compounds referenced herein are intended to encompass pharmaceutically acceptable derivatives including physiologically compatible salts and ester derivatives thereof.


35 The quantity of prostaglandin E₁ in the pharmaceutical compositions of the present invention is a therapeutically effective amount and necessarily varies

- 5 -

according to the desired dose, the dosage form (e.g., suppository or topical), and the particular form of prostaglandin E₁ used. The composition generally contains between 0.1 percent to 1 percent prostaglandin E₁, preferably from 0.3 percent to 0.5 percent, based on the total weight of the composition.

An important component of the present invention is the penetration enhancer. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. For convenient reference, alkyl-2-(N,N-disubstituted amino)-alkanoates and (N,N-disubstituted amino)-alkanol alkanoates can be grouped together under the label alkyl (N,N-disubstituted amino) esters.

Alkyl-2-(N,N-disubstituted amino)-alkanoates suitable for the present invention can be represented as follows:




wherein n is an integer having a value in the range of about 4 to about 18; R is a member of the group consisting of hydrogen, C₁ to C₄ alkyl, benzyl and phenyl; R₁ and R₂ are members of the group consisting of hydrogen and C₁ to C₄ alkyl; and R₃ and R₄ are members of the group consisting of hydrogen, methyl and ethyl.

Preferred alkyl (N,N-disubstituted amino)-alkanoates are C₄ to C₁₈ alkyl (N,N-disubstituted amino)-acetates and C₄ to C₁₈ alkyl (N,N-disubstituted amino)-propionates. Exemplary specific alkyl-2-(N,N-disubstituted amino)-alkanoates include


- 6 -

dodecyl 2-(N,N dimethylamino)-propionate (DDAIP);



and dodecyl 2-(N,N-dimethylamino)-acetate (DDAA);

5




Alkyl-2-(N,N-disubstituted amino)-alkanoates are known. For example, dodecyl 2-(N,N-dimethylamino)-propionate (DDAIP) is available from Steroids, Ltd. (Chicago, IL). In addition, alkyl-2-(N,N-disubstituted amino)-alkanoates can be synthesized from more readily available compounds as described in U.S. Patent No. 4,980,378 to Wong et al..

As described therein, alkyl-2-(N,N-disubstituted amino)-alkanoates are readily prepared via a two-step synthesis. In the first step, long chain alkyl chloroacetates are prepared by reaction of the corresponding long chain alkanols with chloromethyl chloroformate or the like in the presence of an appropriate base such as triethylamine, typically in a suitable solvent such as chloroform. The reaction can


- 7 -

be depicted as follows:



- 5 wherein R, R₃, R₄ and n are defined as above. The reaction temperature may be selected from about 10EC. to about 200EC. or reflux, with room temperature being preferred. The use of a solvent is optional. If a solvent is used, a wide variety of organic solvents may be selected.
- 10 Choice of a base is likewise not critical. Preferred bases include tertiary amines such as triethylamine, pyridine and the like. Reaction time generally extends from about one hour to three days.


- 15 In the second step, the long chain alkyl chloroacetate is condensed with an appropriate amine according to the scheme:



wherein n, R, R₁, R₂, R₃ and R₄ are defined as before. Excess

amine reactant is typically used as the base and the reaction is conveniently conducted in a suitable solvent such as ether. This second step is preferably run at room temperature, although temperature may vary. Reaction time usually varies from about one hour to several days. Conventional purification techniques can be applied to ready the resulting ester for use in a pharmaceutical compound.

Suitable (N,N-disubstituted amino)-alkanol alkanoates can be represented by the formula:




10

wherein n is an integer having a value in the range of about 5 to about 18; y is an integer having a value in the range of 0 to about 5; and R₁, R₂, R₃, R₄, R₅, R₆, and R₇ are members of the group consisting of hydrogen, C₁ to C₈ alkyl, and C₁ to C₈ aryl; and R₈ is a member of the group consisting of hydrogen, hydroxyl, C₁ to C₈ alkyl, and C₁ to C₈ aryl.

15


Preferred (N,N-disubstituted amino)-alkanol alkanoates are C₅ to C₁₈ carboxylic acid esters. Exemplary specific (N,N-disubstituted amino)-alkanol alkanoates include 1- (N,N-dimethylamino) -2-propanol dodecanoate (DAIPD);

20




1- (N,N-dimethylamino) -2-propanol myristate (DAIPM);

- 9 -



1-(N,N-dimethylamino)-2-propanol oleate (DAIPO);



5

The (N,N-disubstituted amino)-alkanol alkanoates are readily prepared by reacting the corresponding aminoalkinol with lauroyl chloride in the presence of triethylamine. A solvent such as chloroform is optional but preferred. For example, 1-(N,N-dimethylamino)-2-propanol can be reacted with lauroyl chloride in chloroform and in the presence of triethylamine to form 1-(N,N-dimethylamino)-2-propanol dodecanoate (DAIPD).

Among the suitable penetration enhancers for the present invention DDAIP is generally preferred.

The penetration enhancer is present in an amount sufficient to enhance the penetration of the prostaglandin E_1 . The specific amount varies necessarily according to the desired release rate and the specific form of prostaglandin E_1 used. Generally, this amount ranges from about 0.5 percent to about 10 percent, based on the total weight of the composition. Preferably, the penetration enhancer is about 5 weight percent of the composition.

Polysaccharide gums are also an important ingredient to the present composition. Suitable representative gums are those in the galactomannan gum category. A galactomannan gum

- 10 -

is a carbohydrate polymer containing D-galactose and D-mannose units, or other derivatives of such a polymer. There is a relatively large number of galactomannans, which vary in composition depending on their origin. The galactomannan gum
5 is characterized by a linear structure of β -D-mannopyranosyl units linked (1 \rightarrow 4). Single membered α -D-manopyranosyl units, linked (1 \rightarrow 6) with the main chain, are present as side branches. Galactomannan gums include guar gum, which is the pulverized endosperm of the seed of either of two leguminous
10 plants (*Cyamposis tetragonalobus* and *psoraloids*) and locust bean gum, which is found in the endosperm of the seeds of the carobtree (*ceratonia siliqua*). Locust bean gum is preferred for the present invention.

Other suitable representative gums include agar gum,
15 carrageenan gum, ghatti gum, karaya gum, rhamsan gum and xanthan gum. The composition of the present invention may contain a mixture of various gums, or mixture of gums and acidic polymers.

Gums, and galactomannan gums in particular, are well-
20 known materials. See for instance, *Industrial Gums: Polysaccharides & Their Derivatives*, Whistler R. L. and BeMiller J.N. (eds.), 3rd Ed. Academic Press (1992) and Davidson R. L., *Handbook of Water-Soluble Gums & Resins*, McGraw-Hill, Inc., N.Y. (1980). Most gums are commercially
25 available in various forms, commonly a powder, and ready for use in foods and topical compositions. For example, locust bean gum in powdered form is available from Tic Gums Inc. (Belcam, MD).

The polysaccharide gums are represent in the range
30 from about 0.5 percent to about 5 percent, based on the total weight of the composition, with the preferred range being from 0.5 percent to 2 percent. Illustrative compositions are given in the examples, below.

An optional alternative to the polysaccharide gum is
35 a polyacrylic acid polymer. A common variety of polyacrylic acid polymer is known generically as "carbomer." Carbomer is

- 11 -

polyacrylic acid polymers lightly cross-linked with polyalkenyl polyether. It is commercially available from the B. F. Goodrich Company (Akron, Ohio) under the designation "CARBOPOL™." A particularly preferred variety of carbomer is that designated as "CARBOPOL 940."

Other polyacrylic acid polymers suitable for use in practicing this invention are those commercially available under the designations "Pemulen™" (B. F. Goodrich Company) and "POLYCARBOPHIL™" (A.H. Robbins, Richmond, VA). The Pemulen™ polymers are copolymers of C₁₀ to C₃₀ alkyl acrylates and one or more monomers of acrylic acid, methacrylic acid or one of their simple esters crosslinked with an allyl ether of sucrose or an allyl ether of pentaerythritol. The POLYCARBOPHIL™ enhancer is a polyacrylic acid cross-linked with divinyl glycol.

Where polyacrylic acid polymers are present, they represent about 0.5 percent to about 5 percent of the composition, based on its total weight.

Another important component of the present invention is a lipophilic compound. The term lipophilic compound as used herein refers to an agent that is both lipophilic and hydrophilic. The C₁ to C₆ aliphatic alcohols, the C₂ to C₃₀ aliphatic esters, and their mixtures can serve as lipophilic compound. Illustrative suitable alcohols are ethanol, n-propanol and isopropanol, while suitable esters are ethyl acetate, butyl acetate, ethyl laurate, methyl propionate and isopropyl myristate. As used herein, the term "aliphatic alcohol" includes polyols such as glycerol, propylene glycol and polyethylene glycols. A mixture of alcohol and ester is preferred, and in particular, a mixture of ethanol and ethyl laurate myristate is most preferred.

The concentration of lipophilic compound required necessarily varies according to other factors such as the desired semi-solid consistency and the desired skin penetration promoting effects. The preferred topical composition contains lipophilic compound in the range of 7 percent to 40 percent by weight based on the total weight of the composition. Where a

12 -

5 mixture of aliphatic alcohol and aliphatic ester are employed, the preferred amount of alcohol is in the range of 5 percent to 15 percent, while that of aliphatic ester is in the range from 2 percent to 15 percent (again based on the total weight of the composition).

10 An optional, but preferred, component of the present invention is an emulsifier. Although not a critical factor, a suitable emulsifier generally will exhibit a hydrophilic-lipophilic balance number greater than 10. Sucrose esters, and specifically sucrose stearate, can serve as emulsifiers for the topical composition of the present invention. Sucrose stearate is a well known emulsifier available from various commercial sources. When an emulsifier is used, sucrose stearate present up to about 2 percent, based on the total weight of the composition, is preferred. The preferred amount of sucrose stearate emulsifier can also be expressed as a weight ratio of emulsifier to polysaccharide gum. A ratio of 1 to 6 emulsifier to gum is preferred, and a ratio of 1 to 4 is most preferred to generate the desired semi-solid consistency and separation resistance.

20 The present invention includes an acid buffer system. Acid buffer systems serve to maintain or buffer the pH of compositions within a desired range. The term "buffer system" or "buffer" as used herein has reference to a solute agent or agents which, when in a water solution, stabilize such solution against a major change in pH (or hydrogen ion concentration or activity) when acids or bases are added thereto. Solute agent or agents which are thus responsible for a resistance to change in pH from a starting buffered pH value in the range indicated above are well known. While there are countless suitable buffers, potassium phosphate monohydrate has proven effective for compositions of the present invention.

30 The final pH value of the pharmaceutical composition of the present invention may vary within the physiologically compatible range. Necessarily, the final pH value is not irritating to human skin. Without violating this constraint,

- 13 -

the pH may be selected to improve prostaglandin E₁ stability and to adjust consistency when required. With these factors accounted for, the preferred pH value is about 3.0 to 7.4. The most preferred pH range is from about 3.5 to about 6.0.

The remaining component of the composition is water, which is necessarily purified. The composition contains water in the range of about 50 to about 90 percent, based on the total weight of the composition. The specific amount of water present is not critical, however, being adjustable to obtain the desired consistency and/or concentration of the other components.

A further embodiment of the present invention is a topical composition which comprises prostaglandin E₁, an alkyl (N,N-disubstituted amino) ester, a polysaccharide gum or a polyacrylic acid polymer, a lipophilic compound and an acidic buffer, which are contained as 0.5 to 5 weight percent locust bean gum, 0.5 to 25 weight percent dodecyl (N,N-dimethyl amino)-proportionate, 0.5 to 80 weight percent ethanol, and 0.5 to 80 weight percent isopropyl myristate, based on the total weight of the composition.

A further embodiment of the present invention is a topical composition which comprises prostaglandin E₁, an alkyl (N,N-disubstituted amino) ester, a polysaccharide gum or a polyacrylic acid polymer, a lipophilic compound and an acidic buffer, which are contained as 0.5 to 5 weight percent locust bean gum, 0.5 to 5 weight percent dodecyl (N,N-dimethyl amino)-proportionate, 0.5 to 25 weight percent ethanol, and 0.5 to 25 weight percent ethyl laurate, based on the total weight of the composition for the manufacture of a topical pharmaceutical dosage form.

- 13a -

Additionally, known transdermal penetration enhancers can also be added, if desired. Illustrative are dimethyl sulfoxide (DMSO), dimethyl acetamide (DMA), 2-pyrrolidone, N,N-diethyl-m-toluamide (DEET), 1-dodecylazacycloheptane-2-one (Azone™, a registered trademark of Nelson Research), N,N-dimethylformamide, N-methyl-2-pyrrolidone, calcium thioglycolate, oxazolidinone, dioxolane derivatives, laurocapram derivatives, and macrocyclic enhancers such as macrocyclic ketones.

Prostaglandin E₁ stabilizers, coloring agents, rheological agents, and preservatives can be added to the extent that they do not overly limit prostaglandin E₁ skin penetration or prevent the desired semi-solid consistency.

Contemplated dosage forms of the semi-solid pharmaceutical composition of the present invention are creams, gels, and the like, also including but not limited to compositions suitable for use with transdermal patches and like devices.

The ingredients listed above may be combined in any order and manner that produces a stable composition comprising a prostaglandin E₁ evenly dispersed throughout a semi-solid formulation. One available approach to preparing such compositions involves evenly dispersing the polysaccharide gum (or polyacrylic acid) in a premixed water/buffer solution and then thoroughly homogenizing (i.e. mixing) the resulting

14 -

mixture, which will be labelled "Part A." When present, the emulsifier is added to the water/buffer solution before dispersing the polysaccharide gum. Any suitable method of adjusting the pH value of Part A to the desired level may be used, for example, by adding concentrated phosphoric acid or sodium hydroxide.

Separately, the prostaglandin E_1 is dissolved with agitation in the lipophilic compound, which itself may be a mixture of alcohols, esters, or alcohol with ester. Next, the penetration enhancer is added. Alternatively, when the lipophilic compound includes both an alcohol and an ester, the prostaglandin E_1 can be dissolved in the alcohol before adding the penetration enhancer followed by the ester. In either case, the resulting mixture will be labelled "Part B." The final step involves slow addition (e.g. dropwise) of Part B into Part A under constant mixing.

The resulting topical composition, when compared to existing commercially available compositions, exhibits the advantageous properties described above, including improved prostaglandin E_1 permeation and bioavailability without drug overloading, reduced damage and related inflammation to skin or mucous membranes, and increased flexibility in design of dosage forms. These compositions can be used for the manufacture of pharmaceutical compositions that are suitable for the prolonged treatment of peripheral vascular disease, male impotency, male erectile dysfunction, female sexual dysfunction and other disorders treated by prostaglandin E_1 , while avoiding the low bioavailability and rapid chemical decomposition associated with other delivery methods. These compositions can be used for the manufacture of pharmaceutical compositions that are suitable for the enhancement of the sexual response of normal (i.e., orgasmic) human females. Application of prostaglandin E_1 in a topical composition of the present invention to the skin or mucous membrane of a patient allows a predetermined amount of prostaglandin E_1 to be administered continuously to the patient and avoids undesirable effects present with a single or

- 15 -

multiple administrations of larger dosages by injection. By maintaining a sustained dosage rate, the prostaglandin E₁ level in the patient's target tissue can be better maintained within the optimal therapeutic range.

5 The practice of the present invention is demonstrated in the following examples. These examples are meant to illustrate the invention rather than to limit its scope. Variations in the treating compositions which do not adversely affect the effectiveness of prostaglandin E₁ will be evident to one skilled in the art, and are within the scope of this invention. For example, additional ingredients such as coloring agents, anti-microbial preservatives, emulsifiers, perfumes, prostaglandin E₁ stabilizers, and the like may be included in the compositions as long as the resulting composition retains desirable properties, as described above. Unless otherwise indicated, each composition is prepared by conventionally admixing the respective indicated components together.

EXAMPLE 1: Topical Prostaglandin E₁ Composition A

20 Composition A was prepared as follows. Part A was formed by dissolving 0.4 parts prostaglandin E₁ (Alprostadil USP) in 5 parts ethyl alcohol. Next, 5 parts dodecyl 2-(N,N-dimethylamino)-propionate were mixed into the alcohol-prostaglandin E₁ solution, followed by 5 parts ethyl laurate.

25 Part B was prepared starting from a pH 5.5 water/buffer solution. The water/buffer solution was prepared by adding sufficient potassium phosphate monohydrate to purified water to create a 0.1 M solution. The pH of the water/buffer solution was adjusted to 5.5 with a strong base solution (1 N sodium hydroxide) and a strong acid (1 N phosphoric acid). The buffer solution represented about 80 parts of the total composition.

35 To the buffer solution, was added 0.5 parts ethyl laurate. Next, the locust bean gum (in powder form) was dispersed in the buffer solution and homogenized using a homogenizer. TABLE 1, below, contains a list of ingredients.

16 -

The resulting composition was a spreadable, semi-solid suitable for application to the skin without the need for supporting devices such as patches and adhesive strips. The composition was both homogenous in appearance and resistant to separation.

Composition A was evaluated for skin penetration using shed snake skin as a model barrier. Shed snake skin was obtained from the Animal Care Unit of the University of Kansas. With head and tail sections removed, the skin was randomly divided into test sections and then hydrated by soaking.

The samples were then evaluated using Franz-type Diffusion Cells (surface area 1.8 cm²). Specifically, skin pieces were mounted on top of a receptor cell of a vertical diffusion cell assembly in which a small magnetic bar was inserted and filled with an isotonic buffer. A seal was placed on top of the skin section followed by a donor cell. The two cells were clamped together. Known amounts of the formulations were applied on the bottom of a small capped vial (weight .5 grams) which fits exactly to the donor cell to ensure uniform distribution. The vials were placed on the skin in the donor cell. To reduce the evaporation of the ingredients, the donor cell and vial were gently taped together with a water-resistant adhesive band. The cells were transferred to a stirred water bath (32°C.). Samples were withdrawn from the cells each hour for four hours and analyzed for the concentration of prostaglandin E₁, with changes in concentration indicating the amount penetrating. Tests with multiple skin samples yielded data that were averaged.

For a discussion of the use of shed snake skin in the evaluation of drug penetration, see U.S. Patent No. 4,771,004 to Higuchi.

The prostaglandin E₁ penetrated quickly at a relatively sustained rate for four hours. The results of the penetration study are presented in TABLE 2, below, and in FIGURE 1.

- 17 -

EXAMPLE 2: Topical Prostaglandin E₁ Composition B

Composition B was prepared using the ingredients listed in TABLE 1, below. Composition B contained more prostaglandin E₁ than Composition A. Despite this increased drug loading, Composition B exhibited a similar semi-solid consistency and homogenous appearance. The penetration of prostaglandin E₁ was measured according to the technique described in Example 1. Composition B provided a relatively fast, sustained delivery of prostaglandin E₁. The results are presented in TABLE 2, below, and in FIGURE 1.

EXAMPLE 3: Topical Prostaglandin E₁ Composition C

Composition C was prepared using the ingredients listed in TABLE 1, below. Composition B contained more prostaglandin E₁ than either Composition A or B. The increased drug loading had little or no effect on the consistency or appearance, which substantially matched that of Compositions A and B. The penetration of prostaglandin E₁ was again measured according to the technique described in Example 1. According to this test, Composition C also provided a relatively fast, sustained delivery of prostaglandin E₁. The results are presented in TABLE 2, below, and in FIGURE 1.

EXAMPLE 4: Topical Prostaglandin E₁ Composition D

Composition D was prepared using the ingredients listed in TABLE 1, below. The level of prostaglandin E₁ was again increased without substantially affecting the favorable consistency and separation resistance. The penetration of prostaglandin E₁ was again measured according to the technique described in Example 1. The results are presented in TABLE 2, below, and in FIGURE 1.

EXAMPLE 5: Topical Prostaglandin E₁ Composition E

Composition E was prepared using the ingredients listed in TABLE 1, below. To assess the repeatability of compositions according to the present invention, the recipe of Composition D was again applied for Composition E.

- 18 -

Repeatability was substantially confirmed by Composition E's favorable, semi-solid consistency and separation resistance. The penetration of prostaglandin E₁ was again measured according to the technique described in Example 1. The prostaglandin E₁ delivery from Composition E was again relatively fast and sustained. The results are presented in TABLE 2, below, and in FIGURE 1.

EXAMPLE 6: Topical Prostaglandin E₁ Composition F

The level of prostaglandin E₁ was again increased for Composition F. The specific ingredients are listed in TABLE 1. The favorable consistency and separation resistance was undiminished. The results of a penetration analysis are presented in TABLE 2, below, and in FIGURE 1.

EXAMPLE 7: Topical Prostaglandin E₁ Composition G

Composition G was prepared using the ingredients listed in TABLE 1. For Composition G, the recipe of Composition F was repeated except that the ester component (ester laurate) was omitted and the level of ethanol was increased a corresponding amount. The resulting composition was also a spreadable, semi-solid having a homogenous appearance and resistance to separation. The results of a penetration analysis are presented in TABLE 2, below, and in FIGURE 1. While still favorable, these results reflect the relative benefit to compositions of the present invention from a lipophilic compound that includes both an ester component and an alcohol component.

TABLE 1: Topical Prostaglandin E₁ Compositions

Ingredient (wt%)		A	B	C	D	E	F	G
Part A:	prehydrated locust bean gum	3	3	3	3	3	3	3
	water/buffer (pH 5.5)	81	81	81	81	81	81	81
	sucrose stearate	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Part B:	prostaglandin E ₁	0.1	0.2	0.3	0.4	0.4	0.5	0.4
	DDAIP	5	5	5	5	5	5	5
	ethanol	5	5	5	5	5	5	10
	ethyl laurate	5	5	5	5	5	5	-

- 19 -

EXAMPLE 8: Comparison of Penetration Profiles

TABLE 2 shows the cumulative amount of prostaglandin E₁ penetrating each hour for 4 hours for each example composition according to the present invention. These data demonstrate the ability of the present invention to delivery prostaglandin E₁ drugs transdermally.

FIGURE 1 is graph generated from the data presented in TABLE 1. Significantly, and well represented in graphical form, compositions according to the present invention deliver effective skin penetration relatively fast and at a sustained rate. As expected, cumulative penetration increases with increased prostaglandin E₁ loading of the source composition.

TABLE 2: Cumulative Prostaglandin E₁ Penetration ($\mu\text{g}/\text{cm}^2$)

Hour	A	B	C	D	E	F	G
1	1.96	3.37	5.47	7.20	7.09	10.38	3.03
2	5.49	9.72	18.06	21.26	18.6	25.03	8.17
3	11.25	18.18	30.34	35.53	28.24	42.18	12.93
4	13.98	23.48	38.49	47.98	41.1	52.13	18.71

To further asses the effectiveness of compositions according the present invention, comparative example compositions were prepared. A first comparative example (Comparative Example 1) was prepared with the same recipe as Compositions D and E except that the DDAIP penetration enhancer was omitted. For A second comparative example (Comparative Example 2), the DDAIP was again omitted, but the level of ethanol was increased a corresponding amount. The specific ingredients used are listed in TABLE 3, below.

- 20 -

TABLE 3: Comparative Examples

	Ingredient (wt%)	Comparative Composition 1	Comparative Composition 2
Part A:	prehydrated locust bean gum	3	3
	water/buffer (pH 5.5)	86	81
	sucrose stearate	0.5	0.5
Part B:	prostaglandin E ₁	0.4	0.4
	ethanol	5	10
	ethyl laurate	5	5

The penetration of prostaglandin E₁ from was evaluated according to the technique described in Example 1. The results are presented in TABLE 4, below.

TABLE 4: Comparative Examples
Cumulative Prostaglandin E₁ Penetration ($\mu\text{g}/\text{cm}^2$)

Hour	Comparative Composition 1	Comparative Composition 2
1	2.64	1.55
2	4.46	3.89
3	6.59	6.63
4	9.67	11.05

10

The data of TABLE 4 are compared graphically to the example compositions having the same prostaglandin E₁ loading, Compositions D and E. The penetration data demonstrate that compositions according to the present invention benefit greatly from the presence of the DDAIP penetration enhancer.

15

The foregoing specification is intended as illustrative and is not to be taken as limiting. Still other variations within the spirit and the scope of the invention are possible and will readily present themselves to those skilled in the art.

20

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVELEDGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. Use of prostaglandin E₁;

5 a skin penetration enhancer which is a member of the group consisting of an alkyl-2-(N,N-disubstituted amino)-alkanoate, an (N,N-disubstituted amino)-alkanol alkanoate, and a mixture thereof;

a polysaccharide gum or a polyacrylic acid polymer;

10 a compound which is a member of the group consisting of an aliphatic C₁ to C₈


alcohol, an aliphatic C₈ to C₃₀ ester, and a mixture thereof; and

an acidic buffer system

15 for the preparation of a topical composition for (i) treating female sexual dysfunction, (ii) enhancing sexual responsiveness in a human female, (iii) enhancing the rate of healing of wounds, ulcers, infections and proliferative and inflammatory skin lesions, or (iv) treating a disease
20 which is a member of the group consisting of Raynaud's phenomenon, Raynaud's disease, Buerger's disease, livedo reticularis, acrocyanosis atherosclerosis, frostbite, vitiligo, alopecia areata, impending gangrene and ischemic disorders.

25

2. The use in accordance with claim 1 wherein said penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate represented by the formula:




30 wherein n is an integer having a value in the range of about

4 to about 18; R is a member of the group consisting of hydrogen, C₁ to C₇ alkyl, benzyl and phenyl; R₁ and R₂ are members of the group consisting of hydrogen and C₁ to C₇ alkyl; and R₃ and R₄ are members of the group consisting of hydrogen, methyl and ethyl.

3. The use in accordance with claim 1 wherein said penetration enhancer is a C₄ to C₁₈ alkyl (N,N-disubstituted amino)-acetate.

4. The use in accordance with claim 1 wherein said penetration enhancer is dodecyl (N,N-dimethylamino)-acetate or dodecyl 2-(N,N-dimethylamino)-propionate.

5. The use in accordance with claim 1 wherein said penetration enhancer is an (N,N-disubstituted amino)-alkanol alkanoate represented by the formula:




wherein n is an integer having a value in the range of about 5 to about 18; y is an integer having a value in the range of 0 to about 5; and R₁, R₂, R₃, R₄, R₅, R₆, and R₇ are members of the group consisting of hydrogen, C₁ to C₈ alkyl, and aryl of up to 8 C-atoms; and R₈ is a member of the group consisting of hydrogen, hydroxyl, C₁ to C₈ alkyl, and aryl of up to 8 C-atoms.

6. The use in accordance with claim 1 wherein said penetration enhancer is a C₅ to C₁₈ carboxylic acid ester.
- 5 7. The use in accordance with claim 1 wherein said penetration enhancer is a member of the group consisting of
1-(N,N-dimethylamino)-2-propanol dodecanoate,
1-(N,N-dimethylamino)-2-propanol myristate and
1-(N,N-dimethylamino)-2-propanol oleate.
- 10 8. The use in accordance with claim 1 wherein said polysaccharide gum is a galactomannan gum.
9. The use in accordance with claim 8 wherein said galactomannan gum is a locust bean gum or a guar gum.
- 15 10. The use in accordance with claim 1 wherein said compound which is a member of the group consisting of an aliphatic C₁ to C₈ alcohol, an aliphatic C₈ to C₃₀ ester, and a mixture thereof is a member of the group consisting of ethanol, a
20 polyol aliphatic alcohol, isopropyl myristate and ethyl laurate.
11. The use in accordance with claim 1 wherein said compound which is a member of the group consisting of an aliphatic C₁ to C₈ alcohol, an aliphatic C₈ to C₃₀ ester, and a mixture
25 thereof is a mixture of ethanol and isopropyl myristate or a mixture of ethanol and ethyl laurate.
12. The use in accordance with any one of claims 1 to 11 wherein
30 said acidic buffer system is capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

13. The use in accordance with claim 1 wherein said penetration enhancer is a dodecyl 2-(N,N-dimethylamino)-propionate, said polysaccharide gum is a locust bean gum, and said compound which is a member of the group consisting of an aliphatic C₁ to C₈ alcohol, an aliphatic C₈ to C₃₀ ester, and a mixture thereof is a mixture of ethanol and ethyl laurate.
14. The use in accordance with claim 1 wherein said topical composition contains 0.5 to 5 weight percent locust bean gum, 0.5 to 25 weight percent dodecyl 2-(N,N-dimethylamino)-propionate, 0.5 to 80 weight percent ethanol, and 0.5 to 80 weight percent isopropyl myristate, based on the total weight of the composition.
15. The use in accordance with claim 1, wherein said topical composition contains 0.5 to 5 weight percent locust bean gum, 0.5 to 5 weight percent dodecyl 2-(N,N-dimethylamino)-propionate, 0.5 to 25 weight percent ethanol, and 0.5 to 25 weight percent ethyl laurate, based on the total weight of the composition.
16. The use in accordance with any one of claims 1 to 15 wherein the topical composition further contains an emulsifier.
17. The use in accordance with claim 16 wherein said emulsifier is an sucrose ester.
18. The use in accordance with claim 17 wherein said sucrose ester is sucrose stearate.
19. The use in accordance with claim 1 wherein said polyacrylic acid polymer is a carbomer.

20. The use in accordance with any one of claims 1 to 19 wherein said topical composition is for transdermal or transmucosal administration.
- 5 21. The use in accordance with any one of claims 1 to 20 wherein said skin lesion is atopic dermatitis, acne and psoriasis.
22. A method of treating a patient in need of therapy comprising topical application of a composition comprising
- 10 prostaglandin E₁;
- a skin penetration enhancer which is a member of the group consisting of an alkyl-2-(N,N-disubstituted amino)-alkanoate, an (N,N-disubstituted amino)-alkanol alkanoate, and a mixture thereof;
- 15 a polysaccharide gum or a polyacrylic acid polymer;
- a compound which is a member of the group consisting of an aliphatic C₁ to C₈
- alcohol, an aliphatic C₈ to C₃₀ ester, and a mixture thereof; and
- 20 an acidic buffer system
- wherein said therapy is selected from the group of (i) treating female sexual dysfunction, (ii) enhancing sexual responsiveness in a human female, (iii) enhancing the rate of healing of wounds, ulcers, infections and proliferative
- 25 and inflammatory skin lesions, or (iv) treating a disease which is a member of the group consisting of Raynaud's phenomenon, Raynaud's disease, Buerger's disease, livedo reticularis, acrocyanosis atherosclerosis, frostbite, vitiligo, alopecia areata, impending gangrene and ischemic
- 30 disorders.

1/2



2/2




FIG. 2

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)